Clinical Trials Logo

Lupus Nephritis clinical trials

View clinical trials related to Lupus Nephritis.

Filter by:

NCT ID: NCT05039619 Recruiting - Lupus Nephritis Clinical Trials

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants

POSTERITY
Start date: May 12, 2022
Phase: Phase 2
Study type: Interventional

This phase II, randomized, double-blind, placebo-controlled study is designed to evaluate the safety, efficacy and pharmacokinetics (PK) of obinutuzumab in adolescent participants (AP) aged 12 to less than 18 with biopsy-confirmed proliferative lupus nephritis (LN). It will also evaluate open label safety and PK of obinutuzumab in pediatric participants (PP), aged 5 to <12 with LN.

NCT ID: NCT04971590 Recruiting - Clinical trials for Systemic Lupus Erythematosus

Study to Assess Demographic, Pharmacologic, Biomarker, Clinical Features and Quality of Life (QoL) of Participants With Lupus Nephritis

Start date: September 14, 2021
Phase:
Study type: Observational

This is a multicenter prospective study to assess clinical characteristics, demographics, treatment and health-related quality of life (HRQoL) of lupus nephritis (LN) participants across 5 Gulf countries (United Arab Emirates [UAE], Qatar, Bahrain, Kuwait and Oman).

NCT ID: NCT04924296 Not yet recruiting - Lupus Nephritis Clinical Trials

A Phase II Study to Evaluate the Efficacy and Safety of SHR-1314 in Lupus Nephritis

Start date: June 28, 2021
Phase: Phase 2
Study type: Interventional

To demonstrate the efficacy of SHR-1314 at Week 12 in subjects with proliferation lupus nephritis in terms of improvement of 24h UPCR, compared to placebo. The study will also assess the safety and tolerability of SHR-1314 in the patient population over the study period.

NCT ID: NCT04894695 Recruiting - Lupus Nephritis Clinical Trials

Urine Exosomes to Identify Biomarkers for LN

Start date: August 2, 2020
Phase:
Study type: Observational

Urine exosomes will be extracted from patients with lupus nephritis, healthy controls, and patients with systemic lupus erythematosus without lupus nephritis. Transcriptome and/or metabonomics sequencing of exosomes will be performed to screen for molecules in the urine exosomes of patients with lupus nephritis that are significantly different from those of the other groups.

NCT ID: NCT04892212 Not yet recruiting - Lupus Nephritis Clinical Trials

Sirolimus in Treatment of Proteinuric Flares of Lupus Nephritis

Start date: June 30, 2021
Phase: Phase 2/Phase 3
Study type: Interventional

This a single-centre, one-arm, open-label pilot study. Eligible patients with mild proteinuric flares of lupus nephritis Class III/IV±V are received sirolimus without changing previous immunosuppressive medication during 12-week follow-up. Primary Objective: - To investigate the efficacy of sirolimus for mild proteinuric flares in patients with Class III/IV±V lupus nephritis Secondary Objective: - To assess the safety and tolerability of sirolimus treatment for mild proteinuric flares in patients with Class III/IV±V lupus nephritis

NCT ID: NCT04883619 Not yet recruiting - Lupus Nephritis Clinical Trials

A Study of Nipocalimab in Adult Participants With Active Lupus Nephritis

Start date: January 15, 2026
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy of nipocalimab versus placebo in participants with active Lupus Nephritis (LN).

NCT ID: NCT04870359 Recruiting - Lupus Nephritis Clinical Trials

Pre-emptive Treatments in Lupus Nephritis Patients With Serological Reactivation

Start date: April 21, 2016
Phase: N/A
Study type: Interventional

The optimal management of asymptomatic serological reactivation (ASR) in lupus nephritis (LN) patients remained undefined. This project aims to investigate the impact of pre-emptive treatment on disease relapse in LN patients who experienced ASR.

NCT ID: NCT04868838 Recruiting - Lupus Nephritis Clinical Trials

Daratumumab to Treat Active Lupus Nephritis

Start date: April 20, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this research is to study the safety and efficacy of daratumumab in inducing complete or partial remission in patients with active lupus nephritis.

NCT ID: NCT04835883 Recruiting - Clinical trials for Systemic Lupus Erythematosus

Exploring the Efficacy and Safety of CS20AT04 (Allogenic Bone Marrow-Derived Stem Cell) in Systemic Lupus Erythematosus Patients

Start date: September 26, 2019
Phase: Phase 2
Study type: Interventional

This is an open-label, one-arm single-center phase Ⅱa study exploring the efficacy and safety of CS20AT04 (HLA-haplo Matched Allogenic Bone Marrow-Derived Stem Cells) in two subpopulation group of systemic lupus erythematosus patients - lupus nephritis and lupus cytopenia.

NCT ID: NCT04756492 Active, not recruiting - Clinical trials for We Aim to Examine the Predictors of Sustained Complete Renal Remission in Patients With Lupus Nephritis at Sohag University Hospital

Prognostic Factors for Treatment Responses in Patients With Active Lupus Nephritis at Sohag University Hospital

Start date: February 15, 2021
Phase:
Study type: Observational

Systemic lupus erythematosus (SLE) is an autoimmune disease which may give rise to multiple organ involvement because of immune complex deposits. Lupus nephritis (LN) is one of the severe manifestations of systemic lupus erythematous (SLE) and a common cause for end-stage renal disease, significantly affecting the survival of SLE patients Immunosuppressive treatment is the major therapy for active LN. Generally, at least six months are needed to assess treatment responses Failure to respond to immunosuppressive therapy can lead to a worsening of renal function